These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 21396501)
21. Systemic infections can decrease the threshold of statin-induced muscle injury. Mahboobi SK; Shohat EZ; Jellinek SP; Rose M South Med J; 2006 Apr; 99(4):403-4. PubMed ID: 16634254 [No Abstract] [Full Text] [Related]
22. [Proximal myopathy secondary to statin treatment in a patient with Hashimoto thyroiditis]. Ferreiro JL; Dapena Mdel C; Suárez RL; Pérez-Argüelles BS; Vázquez CM Endocrinol Nutr; 2009; 56(7):387. PubMed ID: 19883901 [No Abstract] [Full Text] [Related]
23. Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Athyros VG; Tziomalos K; Kakafika AI; Koumaras H; Karagiannis A; Mikhailidis DP Am J Cardiol; 2008 Feb; 101(4):483-5. PubMed ID: 18312762 [TBL] [Abstract][Full Text] [Related]
24. Randomised study to compare the efficacy and safety of isapgol plus atorvastatin versus atorvastatin alone in subjects with hypercholesterolaemia. Jayaram S; Prasad HB; Sovani VB; Langade DG; Mane PR J Indian Med Assoc; 2007 Mar; 105(3):142-5, 150. PubMed ID: 17824470 [TBL] [Abstract][Full Text] [Related]
26. [Atorvastatin . A new generation of hypolipemic agents?]. Azanza JR; Sádaba B; Quetglas EG Rev Med Univ Navarra; 1998; 42(1):51-5. PubMed ID: 10420957 [No Abstract] [Full Text] [Related]
27. Atorvastatin-induced hemorrhagic cystitis: a case report. Martinez-Suarez HJ; Wang R; Faerber GJ Urology; 2009 Mar; 73(3):681.e5-6. PubMed ID: 18468659 [TBL] [Abstract][Full Text] [Related]
28. Myopathy after switching from brand to generic atorvastatin. Awoniyi O; Gosmanov AR J Am Geriatr Soc; 2013 Dec; 61(12):2254-2255. PubMed ID: 24329838 [No Abstract] [Full Text] [Related]
29. Acute rhabdomyolysis after atorvastatin and fusidic acid therapy. Wenisch C; Krause R; Fladerer P; El Menjawi I; Pohanka E Am J Med; 2000 Jul; 109(1):78. PubMed ID: 10991749 [No Abstract] [Full Text] [Related]
30. Hypernatremia due to rhabdomyolysis in a patient on statin. Victor SM; Gnanaraj A; Abraham G; Sankardas MA Saudi J Kidney Dis Transpl; 2011 Sep; 22(5):1037-8. PubMed ID: 21912045 [No Abstract] [Full Text] [Related]
31. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Goldstein MR; Mascitelli L; Pezzetta F Neurology; 2009 Apr; 72(16):1448; author reply 1448-9. PubMed ID: 19380709 [No Abstract] [Full Text] [Related]
33. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Athyros VG; Mikhailidis DP; Papageorgiou AA; Didangelos TP; Peletidou A; Kleta D; Karagiannis A; Kakafika AI; Tziomalos K; Elisaf M Metabolism; 2005 Aug; 54(8):1065-74. PubMed ID: 16092057 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Faergeman O; Hill L; Windler E; Wiklund O; Asmar R; Duffield E; Sosef F; Cardiology; 2008; 111(4):219-28. PubMed ID: 18434729 [TBL] [Abstract][Full Text] [Related]
36. Usefulness of lymphocyte activation test in atorvastatin hypersensitivity. Piñero Saavedra MC; Prados Castaño M; Sánchez B; Lucena Soto JM; Avila Castellanos R; Ortega-Camarero M J Investig Allergol Clin Immunol; 2011; 21(7):574-5. PubMed ID: 22312946 [No Abstract] [Full Text] [Related]
37. Statin-associated myotoxicity in an incarcerated Indigenous youth - the perfect storm. Haysom L; Samaras K; Stapylton C; Wines J Med J Aust; 2015 Apr; 202(7):381-2. PubMed ID: 25877122 [No Abstract] [Full Text] [Related]
39. Problems in dealing with very rare adverse effects of new anticancer drugs: the example of trabectedin. Grosso F; D'Incalci M Tumori; 2011; 97(2):256. PubMed ID: 21617728 [No Abstract] [Full Text] [Related]